Medipost has announced that its allogeneic human umbilical cord blood-derived mesenchymal stem cell product for knee osteoarthritis was featured in the peer-reviewed Orthopaedic Journal of Sports Medicine. The Seoul, Korea–headquartered company specializes in allogeneic umbilical cord blood-derived mesenchymal stem cells for various therapeutic applications. Medipost’s Phase 3 study found that 97% of recipients of its…